查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1672927

核子医学市场中放射性药物按产品类型、应用、最终用户和地区划分

Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, By Application, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 304 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球核医放射性药物市场规模预计为 77.2 亿美元，预计到 2032 年将达到 138.5 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 8.7%。

报告范围 报告详细信息
基准年 2024 2025 年市场规模 77.2亿美元
效能资料 2020-2024 预测期 2025-2032
预测期：2025 年至 2032 年复合年增长率 8.70％ 2032 年金额预测 138.5亿美元
数字。 2025 年核子医学中放射性药物的市场占有率（按地区划分）
核子医学市场中的放射性药物-IMG1

放射性药物是核子医学中用于诊断和治疗目的的放射性药剂。放射性药物透过引入人体的放射性示踪剂发射核辐射（例如伽马射线），在医学影像技术中发挥重要作用。放射性药物由与生物活性药物化合物（例如单株抗体）附着的放射性同位素组成，可选择性地针对组织、器官或细胞。透过在扫描过程中与伽马摄影机进行交互，医生可以非侵入性地获得对代谢、生理和解剖细节的功能洞察。慢性病发病率的上升、容易罹患癌症和心臟病的老年人口的增加以及放射性示踪剂的技术进步可能会推动放射性药物市场的成长。

市场动态

对疾病早期诊断的需求激增、有利的报销政策、医疗支出的增加以及对核医学治疗益处的认识是推动核医学放射性药物市场发展的一些因素。然而，放射性示踪剂的半衰期较短，需要现场製造设施，这增加了设备安装和维护的成本，可能会阻碍市场成长。透过研发合作开发用于神经病学、罕见疾病和个人化医疗的新型放射性示踪剂可以提供成长机会。此外，药物开发和标靶放射治疗等新兴市场的发展也可能推动市场成长。

研究的主要特点

  • 本报告对全球核医放射性药物市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），以 2024 年为基准年。
  • 它还揭示了各个领域的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
  • 它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
  • 该报告涵盖了全球核医放射性药物市场的主要企业概况，基于公司亮点、产品系列、关键亮点、财务绩效和策略等参数。
  • 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球核医放射性药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员将透过全球核医放射性药物市场分析中使用的各种策略矩阵来做出决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要

第三章市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 影响分析
  • 市场趋势
  • 监管情景
  • 收购和合作场景
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

4. 全球核医放射性药物市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 市场影响

5. 2020 年至 2032 年全球核医放射性药物市场（按产品类型划分）（十亿美元）

  • 介绍
  • 核医学诊断
  • SPECT 放射性药物
  • PET 放射性药物
  • 核子医学治疗

6. 2020 年至 2032 年全球核医放射性药物市场应用（单位：十亿美元）

  • 介绍
  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 内分泌学
  • 其他的

7. 2020 年至 2032 年全球核医放射性药物市场（按最终用户划分）（十亿美元）

  • 介绍
  • 医院
  • 门诊手术中心
  • 专科门诊
  • 诊断中心
  • 其他的

8. 2020 年至 2032 年全球核医放射性药物市场（按地区划分）（单位：十亿美元）

  • 介绍
  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第九章 竞争格局

  • 公司简介
    • Progenics Pharmaceuticals, Inc.
    • NorthStar Medical Radioisotopes LLC
    • Curium Pharma
    • Life Molecular Imaging
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco SpA
    • Bayer AG
    • GE Healthcare
    • Jubilant Pharmova Limited
    • Eckert & Ziegler
    • Mallinckrodt
    • NTP Radioisotopes SOC Ltd.
    • Telix Pharmaceuticals, Inc.
    • Nordic Nanovector
    • Y-mAbs Therapeutics, Inc.
    • Siemens Healthineers AG

第 10 章分析师建议

  • 兴衰
  • 一致的机会地图

第 11 章 参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI70

Global Radiopharmaceuticals in Nuclear Medicine Market is estimated to be valued at USD 7.72 Bn in 2025 and is expected to reach USD 13.85 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 7.72 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.70% 2032 Value Projection: USD 13.85 Bn
Figure. Radiopharmaceuticals In Nuclear Medicine Market Share (%), By Region 2025
Radiopharmaceuticals in Nuclear Medicine Market - IMG1

Radiopharmaceuticals are radioactive drugs used in nuclear medicine for both diagnostics and therapeutics purposes. These play a crucial role in medical imaging techniques through emission of nuclear radiation such as gamma rays from radioactive tracers introduced into the body. Radiopharmaceuticals consist of radioactive isotopes bonded to bioactive pharmaceutical compounds like monoclonal antibodies to selectively target tissues, organs or cells. On interaction with gamma cameras during scans, these help physicians gain functional insights into metabolic, physiological and anatomical details non-invasively. Rising prevalence of chronic diseases, growing geriatric population susceptible to cancer and cardiac ailments and technological advancements in radiotracers can drive the growth of radiopharmaceuticals market.

Market Dynamics:

Surging demand for early disease diagnosis, favorable reimbursement policies, increasing healthcare expenditure, and awareness about benefits of nuclear medicine procedures can drive the radiopharmaceuticals in nuclear medicine market. However, short half-lives of radiotracers requiring on-site production facilities and high installation and maintenance costs of equipment can hamper the market growth. Developing new radiotracers for neurology, rare diseases and personalized medicine through R&D collaborations can offer growth opportunities. Emerging applications in drug development and targeted radiotherapy can also drive the market growth.

Key Features of the Study:

  • This report provides in-depth analysis of the global radiopharmaceuticals in nuclear medicine market, and provides market size (USD billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include GE Healthcare, Bracco Imaging S.p.A., Lantheus Medical Imaging Inc., Bayer AG, Novartis AG (Advanced Accelerator Applications), Nordion Inc., and Jubilant DraxImage Inc. dba Jubilant Radiopharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market

Detailed Segmentation-

  • By Product Type
    • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
    • Therapeutic Nuclear Medicine
  • By Application
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
  • By End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Diagnostic Centers
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Progenics Pharmaceuticals, Inc.
    • NorthStar Medical Radioisotopes LLC
    • Curium Pharma
    • Life Molecular Imaging
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco S.p.A.
    • Bayer AG
    • GE Healthcare
    • Jubilant Pharmova Limited
    • Eckert & Ziegler
    • Mallinckrodt
    • NTP Radioisotopes SOC Ltd.
    • Telix Pharmaceuticals, Inc.
    • Nordic Nanovector
    • Y-mAbs Therapeutics, Inc.
    • Siemens Healthineers AG

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Application
    • Market Snapshot, By End User
    • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Radiopharmaceuticals in Nuclear Medicine Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Diagnostic Nuclear Medicine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • SPECT Radiopharmaceuticals
  • PET Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oncology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cardiology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Neurology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Endocrinology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Diagnostic Centers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Radiopharmaceuticals in Nuclear Medicine Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Progenics Pharmaceuticals, Inc.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • NorthStar Medical Radioisotopes LLC
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Curium Pharma
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Life Molecular Imaging
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco S.p.A.
    • Bayer AG
    • GE Healthcare
    • Jubilant Pharmova Limited
    • Eckert & Ziegler
    • Mallinckrodt
    • NTP Radioisotopes SOC Ltd.
    • Telix Pharmaceuticals, Inc.
    • Nordic Nanovector
    • Y-mAbs Therapeutics, Inc.
    • Siemens Healthineers AG

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact